Intravesical Tranexamic Acid for Patients Requiring Continuous Bladder Irrigation in the ED: A Non-Randomized Feasibility Study

Authors

  • Kelly Soros Providence Health Authority https://orcid.org/0000-0003-0405-1318
  • Ali Abdalvand Department of Emergency Medicine, Fraser Health Authority, Royal Columbian and Eagle Ridge Hospitals, University of British Columbia, Port Moody, BC, Canada
  • Ross Soros
  • Vesna Ivkov Department of Emergency Medicine, Fraser Health Authority, New Westminster, BC, Canada,.
  • Kris Suri University of British Columbia, Vancouver, BC, Canada https://orcid.org/0009-0006-1510-0196
  • Helen Marenghi Emergency Department, Eagle Ridge Hospital, Port Moody, BC, Canada
  • Abigail Darby Emergency Department, Royal Columbian Hospital, New Westminster, BC, Canada
  • Angeli Bucovaz Emergency Department, Eagle Ridge Hospital, Port Moody, BC, Canada
  • Wendy Chan : Emergency Department, Royal Columbian Hospital, New Westminster, BC, Canada https://orcid.org/0009-0009-7651-1265
  • Isadora Donoso Emergency Department, Royal Columbian Hospital, New Westminster, BC, Canada https://orcid.org/0009-0002-0301-6166
  • Karin Duggan Emergency Department, Royal Columbian Hospital, New Westminster, BC, Canada https://orcid.org/0009-0002-8329-7016
  • Megan LeComte Emergency Department, Eagle Ridge Hospital, Port Moody, BC, Canada
  • Samantha Morrison Emergency Department, Eagle Ridge Hospital, Port Moody, BC, Canada
  • Esther Kempling Emergency Department, Royal Columbian Hospital, New Westminster, BC, Canada
  • Ashley Tisseur Emergency Department, Royal Columbian Hospital, New Westminster, BC, Canada

DOI:

https://doi.org/10.29173/cjen230

Keywords:

Tranexamic acid, hematuria, urinary retention, continuous bladder irrigation

Abstract

Objectives

Tranexamic Acid (TXA) is a well studied clot stabilizer that may have benefit when used intravesically prior to continuous bladder irrigation (CBI). This study determined the feasibility of conducting a randomized controlled trial using TXA intravesically in patients who present to the emergency department (ED). The study goals were to recruit 20 participants within a six-month time frame and have an 80% recruitment rate.

Methods

Potential participants were identified at triage if they presented with a complaint of hematuria or urinary retention and were over the age of eighteen.  Informed consent was obtained if the patient needed CBI and met inclusion/exclusion criteria. If consented, TXA was instilled intravesically at the start of CBI treatment and the patient was followed until their CBI treatment was complete.

Results

A total of 14 (out of 18) participants were recruited over eight months. The mean age of participants was 74.5 +/- 7.4 years with only one of the 14 participants identifying as female. For resource management, the study was designed to include support from an on-call nurse. The on-call nurse was called seven out of fourteen times and came into hospital one time. Eight participants did not require hospital admission after the TXA intervention.  The mean length of hospital stay for participants was 4.6+/-2.7 days.  The mean ED length of stay was 8.1+/-4.9 hours.  There were no reported adverse events.

Conclusion

The recruitment rate of 78% indicated that the study was acceptable to participants, but we were unable to meet our goal of recruiting 20 participants over six months. Study protocol was followed, and no adverse events were found. 

References

Canadian Institute for Health Information. (2019, July 25th). National Ambulatory Care Reporting System (NACRS) metadata. https://www.cihi.ca/en/national-ambulatory-care-reporting-system-nacrs-metadata.

Canadian Institute for Health Information (2019, July 25th). Patient Cost Estimator. https://www.cihi.ca/en/patient-cost-estimator.2019.

CRASH-2 Trial Collaborators. (2010). Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): A randomised placebo-controlled trial. The Lancet, 376, 23-32.

Dewan, Y., Komolafe, E. O., Mejía-Mantilla, J. H., Perel, P., Roberts, I., Shakur, H., & CRASH-3 Collaborators (2012). CRASH-3 - tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial. Trials, 13, 87. https://doi.org/10.1186/1745-6215-13-87CRASH-3 Trial Collaborators. (2019). Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): A randomised placebo-controlled trial. The Lancet, 394.

Eldridge, S. M., Chan, C. L., Campbell, M. J., Bond, C. M., Hopewell, S., Thabane, L., et al. (2010). CONSORT 2010 statement: Extension to randomised pilot and feasibility trials. BMJ, 355.

Germann, C. A., & Holmes, J. A. (2018). Selected urologic disorders. In: Rosen’s emergency medicine: Concepts and clinical practice. 9th ed. Elsevier.

Groninger, H., & Phillips, J. M. (2012). Gross hematuria: Assessment and management at the end of life. Hospital Palliative Nursing, 14, 184–8.

Ker, K., Beecher, D., & Roberts, I. (2013). Topical application of tranexamic acid for the reduction of bleeding. The Cochrane Library, 7.

Mina, S. H., & Garcia-Perdomo, H. A. (2018). Effectiveness of tranexamic acid for decreasing bleeding in prostate surgery: A systematic review and meta-analysis. Central European Journal of Urology, 71, 72–77.

Moharamzadeh, P., Ojaghihaghighi, S., Amjadi, M., Rahmani, F., & Farjamnia, A. (2017). Effect of tranexamic acid on gross hematuria: A pilot randomized clinical trial study. American Journal of Emergency Medicine, 35, 1922–1925.

National Ambulatory Care Reporting System Metadata. 2019.

Ng, C. (2001). Assessment and intervention knowledge of nurses in managing catheter patency in continuous bladder irrigation following TURP. Urologic nursing, 21, 97-111.

Pavlovic, S., Krstic, N., Stankovic, J., Zivkovic, S., Bagur, N., Vukovic, N., & Milic, V. (2012). Importance of tranexamic acid in pharmacological taking care of bleeding in urological patients. HealthMED, 6, 626–631.

Roberts, I., Shakur, H., Coats, T., Hunt, B., Balogun, E., Barnetson, L., Cook, L., Kawahara, T., Perel, P., Prieto-Merino, D., Ramos, M., Cairns, J., & Guerriero, C. (2013). The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma atients. Health technology assessment (Winchester, England), 17(10), 1–79. https://doi.org/10.3310/hta17100

Downloads

Published

2024-10-30

How to Cite

Soros, K., Abdalvand, A., Soros, R., Ivkov, V., Suri, K., Marenghi, H., … Tisseur, A. (2024). Intravesical Tranexamic Acid for Patients Requiring Continuous Bladder Irrigation in the ED: A Non-Randomized Feasibility Study. Canadian Journal of Emergency Nursing, 47(2), 144–162. https://doi.org/10.29173/cjen230

Issue

Vol. 47 No. 2 (2024): Fall 2024

Section

Peer Reviewed Articles

License

Copyright (c) 2024 Kelly Soros, Ali Abdalvand, Ross Soros, Vesna Ivkov, Kris Suri, Helen Marenghi, Abigail Darby, Angeli Bucovaz, Wendy Chan, Isadora Donoso, Karin Duggan, Megan LeComte, Samantha Morrison, Esther Kempling, Ashley Tisseur

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The Canadian Journal of Emergency Nursing is published Open Access under a Creative Commons CC-BY 4.0 license. Authors retain full copyright.